A clinical trial for patients with Myelin oligodendrocyte glycoprotein antibody disorder (MogAD)
This is a Global, Multicentre Phase III, Randomised, Double-Blind Clinical Trial. The study will include over 150 adults and adolescents (12-18 years of age) with MOGAD from around the world. Participants will be randomly assigned between treatment arms. In Australia 8 sites will participate in the study, located in NSW, Victoria and Western Australia.